SCHEMBL14451968

SCHEMBL14451968

CN(Cc1ccccc1F)C1CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.49
SLC6A3 Q01959 2/20 0.49
TAAR1 Q96RJ0 3/20 0.47
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 1/20 0.45
AOC3 Q16853 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 1/20 0.43
RIPK1 Q13546 1/20 0.43
SUV39H2 Q9H5I1 1/20 0.40
OPRM1 P35372 1/20 0.40
HRH4 Q9H3N8 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16367151 0.92 SLC6A2 (0.44) SLC6A2SLC6A3TAAR1ALDH1A1KDM4E
SCHEMBL3547410 0.82 SLC6A2 (0.45) SLC6A2SLC6A3TAAR1ALDH1A1KDM4E
SCHEMBL2404071 0.82 TAAR1 (0.62) SLC6A2SLC6A3TAAR1ALDH1A1KDM4E
SCHEMBL902293 0.78 NOS3 (0.50) SLC6A2SLC6A3TAAR1ALDH1A1LMNA
SCHEMBL14438317 0.77 SLC6A2 (0.56) SLC6A2SLC6A3TAAR1ALDH1A1KDM4E
SCHEMBL12074134 0.76 TAAR1 (0.63) SLC6A2SLC6A3TAAR1ALDH1A1KDM4E
SCHEMBL30229567 0.73 ALDH1A1 (0.45) SLC6A2SLC6A3ALDH1A1KDM4ERIPK1
SCHEMBL19795252 0.73 KMT2A (0.54) ALDH1A1KDM4ELMNASMN1; SMN2POLB
SCHEMBL19002822 0.73 OPRM1 (0.69) SLC6A2SLC6A3ALDH1A1LMNASMN1; SMN2
SCHEMBL5648981 0.73 SLC6A2 (0.62) SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197522-A1 Dpp-iv inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197522-A1 Dpp-iv inhibitors DPP7, DPP4, DPP3 SLC6A2 1134/4885SLC6A3 349/4885TAAR1 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.